You can buy or sell SPRO and other stocks, options, ETFs, and crypto commission-free!
Spero Therapeutics, Inc. Common Stock, also called Spero Therapeutics, is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Read More Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 15
Will Spero Therapeutics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Spero Therapeutics. As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. SPRO. The stock has moved higher by 3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider SPRO’s recent earnings e...
Simply Wall StFeb 28
What Type Of Shareholder Owns Spero Therapeutics, Inc.’s (NASDAQ:SPRO)?
A look at the shareholders of Spero Therapeutics, Inc. (NASDAQ:SPRO) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that have been privatized tend to have low insider ownership. Spero Therapeutics is a smaller company with a market capitalization of US$210m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups...
Available Mar 14, After Hours